Around 1,400 patients with Lennox-Gastaut Syndrome will be eligible for NHS treatment with UCB's Fintepla after a NICE recommendation.

Bexicaserin is being developed to treat a group of disorders known as developmental and epileptic encephalopathies (DEEs), including Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis ...